Validation of the MuCopilot app for assessing cystic fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the usability and safety of the MuCopilot mobile application, designed to objectively assess lung function and exercise capacity in patients with cystic fibrosis. Participants will use the app to perform unsupervised digital tests at home, collecting data on their condition between clinical visits. The study aims to ensure that patients can use the app effectively and safely, with a focus on minimizing errors and risks. A total of 17 patients will be involved, with assessments conducted in France.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ⩾ 18 years old
* Patients diagnosed with cystic fibrosis
* Enrolled in or benefiting of a Social Security program
* Having read the information sheet and signed the informed consent form
* Owning a personal smartphone which version is above 14 for IOS and 8 for Android included with a good internet connexion
* Able to read French and understand pictograms on a smartphone app

Exclusion Criteria:

* History of lung transplantation
* Pregnant women and women who are breastfeeding
* Any medical condition that could interfere with the proper conduct and results of the study (clinician's judgement)
* Illiterate in French
* Inability to use a smartphone or MuCopilot application
* Person under legal protection (including guardianship or curatorship)

Where it's running

• CRCM Mixte - Hôpital Charles Nicolle
  Rouen, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older

  This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07485543

• VX-272 dose escalation in healthy adults

  This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Tempe, Arizona · NCT07437105

• Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis

  This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07342920

• Dose escalation of VX-581 to check safety and drug levels in healthy adults

  The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Overland Park, Kansas · NCT07283770

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Collecting sputum samples at home for cystic fibrosis patients

  This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.

  Recruiting at 4 sites University of Pennsylvania · Denver, Colorado and 3 other locations · NCT06950892

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.